Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allon Therapeutics has received US patent for covering the composition of matter of preclinical compound AL-408, the D-isomer of NAP (davunetide).
Subscribe to our email newsletter
AL-408 has been proven to have potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity, the data from pre-clinical studies says.
In an animal model of fetal alcohol syndrome, AL-408 showed better survival and cognitive performance besides neuroprotective activity in a preclinical model of amyotrophic lateral sclerosis
Allon vice president of Commercial Research Dr. Alistair Stewart said the technology platform of neuroprotective peptides derived from naturally occurring brain proteins shows broad neuroprotective effects in a variety of diseases and conditions.
"AL-408 has shown some interesting early-stage research results in areas outside of neurodegenerative diseases, further diversifying and adding value to our product pipeline," Stewart added.